In the biomedical arena, philanthropy is being deployed with increasing sophistication to de-risk investment in medical product development as well as to invest directly in companies with some expectation of return. But the broader community of impact investors downstream of philanthropy has not turned its attention to this space, and development of ESG (environment, social and governance) metrics in this area has been slow. This session will be an opportunity to explore what might be needed to engage a larger pool of capital to support earlier stage, higher risk science—or perhaps to advance deprioritized assets with scientific merit—that could be game-changing for patients. How can we leverage the power of these funds to fuel medical research in areas where the need is greatest? What changes do we want to see in biomedical R&D that that could be driven by investors interested in social benefit?